Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00370981 · ClinicalTrials.gov registry record · Phase 2
Exploratory Study of Pagoclone in Men With Premature Ejaculation.
A Phase 2 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT00370981: Completed Phase 2 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
NCT00370981 is a Phase 2 study that has completed, run by Endo USA Inc., a Keenova Therapeutics Company. The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00370981, a Phase 2 study, has completed, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate pagoclone in the treatment of premature ejaculation.
Interventions
- DRUG pagoclone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2006-07 |
| Est. Completion | 2006-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00370981
The ClinicalTrials.gov registry entry for NCT00370981 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endo USA Inc., a Keenova Therapeutics Company, which has 61 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which pagoclone is the first listed.
NCT00370981 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00370981 about?
NCT00370981 is a clinical study titled "Exploratory Study of Pagoclone in Men With Premature Ejaculation.". The purpose of this study is to evaluate pagoclone in the treatment of premature ejaculation.
What is the current status of trial NCT00370981?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2006-07. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00370981?
The interventions under investigation include: pagoclone (DRUG).
Who is sponsoring clinical trial NCT00370981?
This trial is sponsored by Endo USA Inc., a Keenova Therapeutics Company, which has 61 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.